TrovaGene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop targeted therapies for the treatment of patients with leukemias, lymphomas and solid tumor cancers. Co.'s drug candidate, onvansertib, is an oral and highly-selective Polo-like Kinase 1 (PLK1) adenosine triphosphate competitive inhibitor. PLK1 is essential for regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response. Co.'s intellectual property and proprietary technology enables it to analyze circulating tumor DNA and clinically actionable markers for predicting response to cancer therapies. We show 9 historical shares outstanding datapoints in our coverage of TROV's shares outstanding history.
Understanding the changing numbers of TROV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TROV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TROV by allowing them to research TROV shares outstanding history
as well as any other stock in our coverage universe. |
Free TROV Email Alerts:
Video: Shares Outstanding Importance
